Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Common Equity (2020 - 2025)

Pulse Biosciences has reported Common Equity over the past 6 years, most recently at $92.7 million for Q3 2025.

  • Quarterly results put Common Equity at $92.7 million for Q3 2025, up 17.14% from a year ago — trailing twelve months through Sep 2025 was $92.7 million (up 17.14% YoY), and the annual figure for FY2024 was $114.9 million, up 158.93%.
  • Common Equity for Q3 2025 was $92.7 million at Pulse Biosciences, down from $104.5 million in the prior quarter.
  • Over the last five years, Common Equity for PLSE hit a ceiling of $118.5 million in Q1 2025 and a floor of -$10.7 million in Q1 2023.
  • Median Common Equity over the past 5 years was $44.4 million (2021), compared with a mean of $49.4 million.
  • Peak annual rise in Common Equity hit 2073.31% in 2023, while the deepest fall reached 151.29% in 2023.
  • Pulse Biosciences' Common Equity stood at $44.4 million in 2021, then plummeted by 105.07% to -$2.2 million in 2022, then skyrocketed by 2073.31% to $44.4 million in 2023, then skyrocketed by 158.93% to $114.9 million in 2024, then decreased by 19.3% to $92.7 million in 2025.
  • The last three reported values for Common Equity were $92.7 million (Q3 2025), $104.5 million (Q2 2025), and $118.5 million (Q1 2025) per Business Quant data.